Skip to main content
Jatin Shah, MD, Oncology, Houston, TX, University of Texas M.D. Anderson Cancer Center

JatinShahMD

Oncology Houston, TX

Associate Professor

Dr. Shah is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Shah's full profile

Already have an account?

Education & Training

  • University of Alabama Medical Center
    University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationResidency, Internal Medicine, 2001 - 2004
  • Ohio State University College of Medicine
    Ohio State University College of MedicineClass of 2001

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 2007 - 2025

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...
    Jatin Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
    Jatin Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
    Jatin J. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The ... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Updated Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myel... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-1287, an Investigational Oral CDK9 Inhibitor for the Treatment of Ewing Sarcoma
    Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-1287, an Investigational Oral CDK9 Inhibitor for the Treatment of Ewing SarcomaApril 10th, 2023
  • Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-3654, an Investigational Oral Inhibitor of PIM Kinases for the Treatment of Myelofibrosis
    Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-3654, an Investigational Oral Inhibitor of PIM Kinases for the Treatment of MyelofibrosisJune 8th, 2022
  • Rakesh Roshan on His Battle with Cancer: I Was Sure I Had Cancer Even Before the Reports Came
    Rakesh Roshan on His Battle with Cancer: I Was Sure I Had Cancer Even Before the Reports CameOctober 19th, 2019
  • Join now to see all

Hospital Affiliations